NCT01496989View on ClinicalTrials.gov

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV-MAG (3,000mcg)

Delivered intramuscularly by in vivo electroporation

BIOLOGICAL

GENEVAX® IL-12 (100mcg)

Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation

BIOLOGICAL

GENEVAX® IL-12 (1000mcg)

Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation

BIOLOGICAL

Ad35-GRIN/ENV

(2x10\^10vp) Delivered intramuscularly by standard needle injection

Trial Locations (3)

Unknown

Kenya AIDS Vaccine Initiative, Kangemi, Nairobi

Projet San Francisco, Kigali

Uganda Virus Research Institute-IAVI, Entebbe

Sponsors
All Listed Sponsors
collaborator

Auro Vaccines LLC

INDUSTRY

collaborator

Ichor Medical Systems Incorporated

INDUSTRY

lead

International AIDS Vaccine Initiative

NETWORK

NCT01496989 - Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers | Biotech Hunter | Biotech Hunter